BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK;  HEPNET. Greece Cohort Study Group. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut. 2011;60:1109-1116. [PMID: 21270118 DOI: 10.1136/gut.2010.221846] [Cited by in Crossref: 119] [Cited by in F6Publishing: 121] [Article Influence: 11.9] [Reference Citation Analysis]
Number Citing Articles
1 Kwon JH, Jang JW, Choi JY, Park CH, Yoo SH, Bae SH, Yoon SK. Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment? J Med Virol. 2013;85:34-42. [PMID: 23154874 DOI: 10.1002/jmv.23421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
2 Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. World J Hepatol 2015;7:1097-104. [PMID: 26052398 DOI: 10.4254/wjh.v7.i8.1097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
3 Kim MN, Han KH, Ahn SH. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination. Semin Oncol. 2015;42:316-328. [PMID: 25843736 DOI: 10.1053/j.seminoncol.2014.12.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
4 Strasser SI. Managing hepatitis B to prevent liver cancer: recent advances. Expert Rev Gastroenterol Hepatol 2014;8:409-15. [PMID: 24580046 DOI: 10.1586/17474124.2014.893823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Wong WW, Hicks LK, Tu HA, Pritchard KI, Krahn MD, Feld JJ, Chan KK. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Res Treat 2015;151:639-52. [PMID: 25962692 DOI: 10.1007/s10549-015-3382-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
6 Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Papanikolaou V, Akriviadis E. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int. 2014;27:1022-1028. [PMID: 24909714 DOI: 10.1111/tri.12370] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
7 Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol. 2017;11:1095-1104. [PMID: 28752768 DOI: 10.1080/17474124.2017.1361822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
8 European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185. [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010] [Cited by in Crossref: 2167] [Cited by in F6Publishing: 2017] [Article Influence: 240.8] [Reference Citation Analysis]
9 Wei Y, Yi Y, Tao C, Ye W, Zhao W. Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas. Cancer Manag Res 2019;11:8475-86. [PMID: 31572002 DOI: 10.2147/CMAR.S201744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
11 Tawada A, Kanda T, Imazeki F, Yokosuka O. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int 2016;10:574-93. [PMID: 27026375 DOI: 10.1007/s12072-016-9720-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
12 Qu J, Yu Z, Li Q, Chen Y, Xiang D, Tan L, Lei C, Bai W, Li H, Shang Q, Chen L, Hu X, Lu W, Li Z, Chen D, Wang X, Zhang C, Xiao G, Qi X, Chen J, Zhou L, Chen G, Li Y, Zeng Z, Rong G, Dong Z, Chen Y, Lou M, Wang C, Lu Y, Zhang C, Yang Y. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial. Trials. 2014;15:438. [PMID: 25381721 DOI: 10.1186/1745-6215-15-438] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
13 Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol. 2014;61:408-417. [PMID: 24801416 DOI: 10.1016/j.jhep.2014.04.041] [Cited by in Crossref: 146] [Cited by in F6Publishing: 140] [Article Influence: 20.9] [Reference Citation Analysis]
14 Nayagam S, Thursz M. Strategies for Global Elimination of Chronic HBV Infection: 2019 Update. Curr Hepatology Rep 2019;18:300-9. [DOI: 10.1007/s11901-019-00478-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
15 Al-Hamoudi W, Elsiesy H, Bendahmash A, Al-Masri N, Ali S, Allam N, Al Sofayan M, Al Bahili H, Al Sebayel M, Broering D, Saab S, Abaalkhail F. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. World J Gastroenterol 2015;21:8140-7. [PMID: 26185387 DOI: 10.3748/wjg.v21.i26.8140] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kim MN, Hwang SG, Rim KS, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. Liver Int 2017;37:1788-95. [PMID: 28418595 DOI: 10.1111/liv.13450] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
17 Della Corte C, Aghemo A, Colombo M. Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies. World J Gastroenterol 2013;19:1359-71. [PMID: 23538741 DOI: 10.3748/wjg.v19.i9.1359] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
18 Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol. 2017;67:1281-1297. [PMID: 28736138 DOI: 10.1016/j.jhep.2017.07.011] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 16.8] [Reference Citation Analysis]
19 Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World J Hepatol. 2019;11:65-73. [PMID: 30705719 DOI: 10.4254/wjh.v11.i1.65] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Ben Ari Z, Weitzman E, Safran M. Oncogenic Viruses and Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:341-60. [DOI: 10.1016/j.cld.2015.01.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
21 Huang C, Shen D, Sun S, Huang Y, Xin Y, Luo H, Chen Y, Zhou Z, Liu F, Chen X. Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies. Medicine (Baltimore) 2019;98:e15297. [PMID: 31027094 DOI: 10.1097/MD.0000000000015297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Isorce N, Testoni B, Locatelli M, Fresquet J, Rivoire M, Luangsay S, Zoulim F, Durantel D. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antiviral Res. 2016;130:36-45. [PMID: 26971407 DOI: 10.1016/j.antiviral.2016.03.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
23 Alibek K, Bekmurzayeva A, Mussabekova A, Sultankulov B. Using antimicrobial adjuvant therapy in cancer treatment: a review. Infect Agent Cancer 2012;7:33. [PMID: 23164412 DOI: 10.1186/1750-9378-7-33] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
24 Chen TM, Chang CC, Huang PT, Wen CF, Lin CC. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients. Aliment Pharmacol Ther. 2013;37:243-251. [PMID: 23171385 DOI: 10.1111/apt.12144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
25 Chou R, Blazina I, Bougatsos C, Holmes R, Selph S, Grusing S, Jou J. Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2020;324:2423-36. [PMID: 33320229 DOI: 10.1001/jama.2020.19750] [Reference Citation Analysis]
26 Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014;109:1223-1233. [PMID: 24890440 DOI: 10.1038/ajg.2014.145] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 8.1] [Reference Citation Analysis]
27 Huang G, Li P, Lau WY, Pan Z, Zhao L, Wang Z, Wang M, Zhou W. Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels: A Randomized Controlled Trial. Annals of Surgery 2018;268:943-54. [DOI: 10.1097/sla.0000000000002727] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
28 Wu CC, Fang CY, Hsu HY, Chuang HY, Cheng YJ, Chen YJ, Chou SP, Huang SY, Lin SF, Chang Y, Tsai CH, Chen JY. EBV reactivation as a target of luteolin to repress NPC tumorigenesis. Oncotarget 2016;7:18999-9017. [PMID: 26967558 DOI: 10.18632/oncotarget.7967] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
29 Shim J, Oh CH, Kim JW, Lee CK, Kim B. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy. Scandinavian Journal of Gastroenterology 2017. [DOI: 10.1080/00365521.2017.1335773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
30 Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med. 2015;5. [PMID: 25833942 DOI: 10.1101/cshperspect.a021501] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 15.3] [Reference Citation Analysis]
31 Pellicelli AM, Vignally P, Messina V, Izzi A, Mazzoni E, Barlattani A, Bacca D, Romano M, Mecenate F, Stroffolini T, Furlan C, Picardi A, Gentilucci UV, Gulminetti R, Bonaventura ME, Villani R, D’ambrosio C, Paffetti A, Mastropietro C, Marignani M, Fondacaro L, Cerasari G, Andreoli A, Barbarini G. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. Annals of Hepatology 2014;13:376-85. [DOI: 10.1016/s1665-2681(19)30844-0] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
32 Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J 2021;18:114. [PMID: 34082765 DOI: 10.1186/s12985-021-01589-x] [Reference Citation Analysis]
33 Yang HY, Zheng NQ, Li DM, Gu L, Peng XM. Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion. Virol J 2014;11:165. [PMID: 25224377 DOI: 10.1186/1743-422X-11-165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
34 Liaw YF. Impact of therapy on the outcome of chronic hepatitis B. Liver Int. 2013;33 Suppl 1:111-115. [PMID: 23286854 DOI: 10.1111/liv.12057] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
35 Wang H, Lai H, Hu T, Su W, Lu S, Lin C, Hung C, Chuang P, Wang J, Lee M, Chen C, Peng C. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy: Modified FIB-4 index and hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2019;34:442-9. [DOI: 10.1111/jgh.14372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
36 Kim HS, Kim BK, Kim SU, Park JY, Kim DY, Song KJ, Park JW, Kim YJ, Baatarkhuu O, Han KH, Ahn SH. Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol 2016; 14: 1647-1656. e6. [PMID: 27305847 DOI: 10.1016/j.cgh.2016.05.039] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
37 Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442-450. [PMID: 22504333 DOI: 10.1016/j.jhep.2012.02.033] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 13.2] [Reference Citation Analysis]
38 Goto K, Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol. 2015;50:261-272. [PMID: 25270965 DOI: 10.1007/s00535-014-1000-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
39 Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956-967. [PMID: 25595883 DOI: 10.1016/j.jhep.2015.01.002] [Cited by in Crossref: 247] [Cited by in F6Publishing: 231] [Article Influence: 41.2] [Reference Citation Analysis]
40 Seto W, Fung J, Yuen M, Lai C. Future Prevention and Treatment of Chronic Hepatitis B Infection. Journal of Clinical Gastroenterology 2012;46:725-34. [DOI: 10.1097/mcg.0b013e3182610191] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
41 Heriyanto DS, Yano Y, Utsumi T, Anggorowati N, Rinonce HT, Lusida MI, Soetjipto C, Ratnasari N, Maduseno S, Purnama PB. Mutations within enhancer II and BCP regions of hepatitis B virus in relation to advanced liver diseases in patients infected with subgenotype B3 in Indonesia. J Med Virol. 2012;84:44-51. [PMID: 22095534 DOI: 10.1002/jmv.22266] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
42 Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen CL, Kao JH; C-TEAM study group and the Taiwan Liver Diseases Consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755-1764. [PMID: 27634134 DOI: 10.1111/liv.13253] [Cited by in Crossref: 108] [Cited by in F6Publishing: 91] [Article Influence: 21.6] [Reference Citation Analysis]
43 Colombo M, Iavarone M. Role of antiviral treatment for HCC prevention. Best Pract Res Clin Gastroenterol 2014;28:771-81. [PMID: 25260307 DOI: 10.1016/j.bpg.2014.07.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
44 Della Corte C, Triolo M, Iavarone M, Sangiovanni A. Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver Int 2016;36:166-76. [PMID: 26386254 DOI: 10.1111/liv.12965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
45 Li L, Liu W, Chen YH, Fan CL, Dong PL, Wei FL, Li B, Chen DX, Ding HG. Antiviral drug resistance increases hepatocellular carcinoma: a prospective decompensated cirrhosis cohort study. World J Gastroenterol. 2013;19:8373-8381. [PMID: 24363530 DOI: 10.3748/wjg.v19.i45.8373] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
46 Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN;  HepNet. Greece Study Group. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. J Viral Hepat. 2015;22:120-127. [PMID: 25040685 DOI: 10.1111/jvh.12283] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
47 Mak LY, Ko M, To E, Wong DK, Ma JH, Hui TL, Seto WK, Fung J, Lai CL, Yuen MF. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. J Gastroenterol Hepatol 2019;34:1817-23. [PMID: 30786068 DOI: 10.1111/jgh.14637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
48 Demir M, Grünewald F, Lang S, Schramm C, Bowe A, Mück V, Kütting F, Goeser T, Steffen HM. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) 2016;95:e4602. [PMID: 27661015 DOI: 10.1097/MD.0000000000004602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Abd El Aziz MA, Sacco R, Facciorusso A. Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review. Antivir Chem Chemother 2020;28:2040206620921331. [PMID: 32418480 DOI: 10.1177/2040206620921331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Niederau C. Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014;20:11595-617. [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
51 Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. World J Gastroenterol 2021;27:2025-38. [PMID: 34007137 DOI: 10.3748/wjg.v27.i17.2025] [Reference Citation Analysis]
52 Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57:399-408. [PMID: 22806323 DOI: 10.1002/hep.25937] [Cited by in Crossref: 137] [Cited by in F6Publishing: 131] [Article Influence: 17.1] [Reference Citation Analysis]
53 Aghemo A, Lampertico P, Colombo M. Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense. Journal of Hepatology 2012;57:1326-35. [DOI: 10.1016/j.jhep.2012.06.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
54 Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444-1453. [PMID: 28622419 DOI: 10.1002/hep.29320] [Cited by in Crossref: 151] [Cited by in F6Publishing: 137] [Article Influence: 37.8] [Reference Citation Analysis]
55 Chung HA, Kim JH, Hwang Y, Choi HS, Ko SY, Choe WH, Kwon SY. Noninvasive fibrosis marker can predict recurrence of hepatocellular carcinoma after radiofrequency ablation. Saudi J Gastroenterol 2016;22:57-63. [PMID: 26831608 DOI: 10.4103/1319-3767.173760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
56 Norman GL, Gatselis NK, Shums Z, Liaskos C, Bogdanos DP, Koukoulis GK, Dalekos GN. Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. World J Hepatol 2015;7:1875-83. [PMID: 26207169 DOI: 10.4254/wjh.v7.i14.1875] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
57 Mak LY, Ko KL, To WP, Wong DK, Seto WK, Fung J, Yuen MF. Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. Gut Liver 2020;14:665-8. [PMID: 32457279 DOI: 10.5009/gnl19434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Papatheodoridis GV. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues? Liver Int. 2013;33 Suppl 1:151-156. [PMID: 23286859 DOI: 10.1111/liv.12054] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
59 Ridruejo E. Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma? Expert Opin Drug Saf 2015;14:439-51. [PMID: 25547687 DOI: 10.1517/14740338.2015.998649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
60 Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014;20:7207-12. [PMID: 24966590 DOI: 10.3748/wjg.v20.i23.7207] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
61 Zoulim F, Lebossé F, Levrero M. Current treatments for chronic hepatitis B virus infections. Curr Opin Virol 2016;18:109-16. [PMID: 27318098 DOI: 10.1016/j.coviro.2016.06.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
62 Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol. 2016;22:319-326. [PMID: 27729632 DOI: 10.3350/cmh.2016.0045] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 9.4] [Reference Citation Analysis]
63 Khoo T, Lam D, Olynyk JK. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. WJG 2021;27:4831-45. [DOI: 10.3748/wjg.v27.i29.4831] [Reference Citation Analysis]
64 Demir M, Nigemeier J, Kütting F, Bowe A, Schramm C, Hoffmann V, Waldschmidt D, Goeser T, Steffen HM. Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center. Infection 2015;43:153-62. [PMID: 25701223 DOI: 10.1007/s15010-015-0751-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
65 Ozaras R, Khodor H, Yetim N, Unal UK, Demirhan YE, Gultekin G, Isal B. Monotherapy for hepatitis B infection: a review of treatment options. Expert Rev Anti Infect Ther 2015;13:1457-68. [PMID: 26414781 DOI: 10.1586/14787210.2015.1093934] [Reference Citation Analysis]
66 Wang JY. Antiviral therapy for hepatitis B virus-related decompensated cirrhosis. J Dig Dis. 2012;13:555-557. [PMID: 23107441 DOI: 10.1111/j.1751-2980.2012.00630.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
67 Chauhan R, Lingala S, Gadiparthi C, Lahiri N, Mohanty SR, Wu J, Michalak TI, Satapathy SK. Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management. World J Hepatol. 2018;10:352-370. [PMID: 29599899 DOI: 10.4254/wjh.v10.i3.352] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 7.3] [Reference Citation Analysis]
68 Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015;7:1742-54. [PMID: 26167247 DOI: 10.4254/wjh.v7.i13.1742] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
69 An J, Lee HC. Surveillance for hepatocellular carcinoma in chronic hepatitis B virus infection: for whom. Hepat Oncol. 2015;2:225-229. [PMID: 30191004 DOI: 10.2217/hep.15.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64:1289-1295. [PMID: 25011935 DOI: 10.1136/gutjnl-2014-307023] [Cited by in Crossref: 125] [Cited by in F6Publishing: 115] [Article Influence: 17.9] [Reference Citation Analysis]
71 Jiang XY, Huang B, Huang DP, Wei CS, Zhong WC, Peng DT, Huang FR, Tong GD. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. World J Gastroenterol 2021;27:1101-16. [PMID: 33776376 DOI: 10.3748/wjg.v27.i11.1101] [Reference Citation Analysis]
72 Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues. J Viral Hepat. 2013;20:502-509. [PMID: 23730844 DOI: 10.1111/jvh.12054] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
73 Maier M, Liebert UG, Wittekind C, Kaiser T, Berg T, Wiegand J. Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B. PLoS One. 2013;8:e67481. [PMID: 23826307 DOI: 10.1371/journal.pone.0067481] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
74 Lee JI, Lee HW, Kim SU, Ahn SH, Lee KS. Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. Cancers (Basel) 2019;11:E425. [PMID: 30934621 DOI: 10.3390/cancers11030425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
75 Mazioti A, Gatselis NK, Rountas C, Zachou K, Filippiadis DK, Tepetes K, Koukoulis GK, Fezoulidis I, Dalekos GN. Safety and efficacy of transcatheter arterial chemoemboliazation in the real-life management of unresectable hepatocellular carcinoma. Hepat Mon. 2013;13:e7070. [PMID: 24198841 DOI: 10.5812/hepatmon.7070.] [Reference Citation Analysis]
76 Barth C, Neusser S, Biermann J, Wasem J, Berg T, Wiegand J, Wolffram I, Petroff D, Aidelsburger P, Grünbauer A, Neumann A. Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting. Scand J Gastroenterol 2018;53:76-82. [PMID: 29065740 DOI: 10.1080/00365521.2017.1390599] [Reference Citation Analysis]
77 Kim BS, Seo YS, Kim YS, Lee CH, Lee HA, Um SH, Yoo J, Kim SG, Suh SJ, Jung YK, Ahn SH, Han K, Yim HJ, Kim SU; The Korean Transient Elastography Study Group. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis: Subcirrhotic liver stiffness in HBV. Journal of Gastroenterology and Hepatology 2018;33:503-10. [DOI: 10.1111/jgh.13854] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
78 Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol 2015;7:1064-73. [PMID: 26052395 DOI: 10.4254/wjh.v7.i8.1064] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
79 Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, Nam SW, Bae SH, Choi JY, Yoon SK, Han NI, Jang JW. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut 2020;69:1301-8. [PMID: 31672838 DOI: 10.1136/gutjnl-2019-318947] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 15.5] [Reference Citation Analysis]
80 Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. Journal of Hepatology 2015;62:363-70. [DOI: 10.1016/j.jhep.2014.08.045] [Cited by in Crossref: 107] [Cited by in F6Publishing: 99] [Article Influence: 17.8] [Reference Citation Analysis]
81 D'Ambrosio R, Della Corte C, Colombo M. Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy. Int J Mol Sci. 2015;16:19698-19712. [PMID: 26295392 DOI: 10.3390/ijms160819698] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
82 Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH, Peng CY. On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1177. [PMID: 32392752 DOI: 10.3390/cancers12051177] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
83 Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749-1761. [PMID: 24480518 DOI: 10.1016/s0140-6736(14)60121-5] [Cited by in Crossref: 801] [Cited by in F6Publishing: 360] [Article Influence: 114.4] [Reference Citation Analysis]
84 Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS One 2017;12:e0188552. [PMID: 29176777 DOI: 10.1371/journal.pone.0188552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Azmi AN, Tan SS, Mohamed R. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol 2014;20:12045-55. [PMID: 25232242 DOI: 10.3748/wjg.v20.i34.12045] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
86 Kim MN, Hwang SG, Kim BK, Park JY, Kim DY, Han KH, Kim SU, Ahn SH. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Gut Liver 2019;13:197-205. [PMID: 30602075 DOI: 10.5009/gnl18204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
87 Coffin CS, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, Myers RP. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther. 2014;40:1262-1269. [PMID: 25312649 DOI: 10.1111/apt.12990] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
88 van Bömmel F, Berg T. Treatment of HBV related cirrhosis. Liver Int. 2013;33 Suppl 1:176-181. [PMID: 23286862 DOI: 10.1111/liv.12074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
89 Wu SD, Liu LL, Cheng JL, Liu Y, Cheng LS, Wang SQ, Ma W, Chen LP, Tseng YJ, Wang JY, Shen XZ, Jiang W. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment. Clin Exp Med. 2018;18:433-443. [PMID: 29696462 DOI: 10.1007/s10238-018-0501-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
90 Triolo M, Della Corte C, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int. 2014;34 Suppl 1:139-145. [PMID: 24373091 DOI: 10.1111/liv.12394] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
91 Mazioti A, Gatselis NK, Rountas C, Zachou K, Filippiadis DK, Tepetes K, Koukoulis GK, Fezoulidis I, Dalekos GN. Safety and efficacy of transcatheter arterial chemoemboliazation in the real-life management of unresectable hepatocellular carcinoma. Hepat Mon. 2013;13:e7070. [PMID: 24198841 DOI: 10.5812/hepatmon.7070] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
92 Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011;66:2715-2725. [PMID: 21965435 DOI: 10.1093/jac/dkr388] [Cited by in Crossref: 117] [Cited by in F6Publishing: 98] [Article Influence: 11.7] [Reference Citation Analysis]
93 Seto WK, Lau EH, Wu JT, Hung IF, Leung WK, Cheung KS, Fung J, Lai CL, Yuen MF. Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. Aliment Pharmacol Ther. 2017;45:501-509. [PMID: 27976416 DOI: 10.1111/apt.13895] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
94 Wang B, Agarwal K, Joshi D. Management of chronic hepatitis B before and after liver transplantation. Frontline Gastroenterol 2018;9:79-84. [PMID: 29484165 DOI: 10.1136/flgastro-2016-100768] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Liang KH, Ahn SH, Lee HW, Huang YH, Chien RN, Hu TH, Lin KH, Yeh CS, Hsu CW, Lin CL, Pan TL, Ke PY, Chang ML, Yeh CT. A novel risk score for hepatocellular carcinoma in Asian cirrhotic patients: a multicentre prospective cohort study. Sci Rep 2018;8:8608. [PMID: 29872158 DOI: 10.1038/s41598-018-26992-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
96 Wong GL, Wong VW. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol. 2013;19:6515-6522. [PMID: 24151375 DOI: 10.3748/wjg.v19.i39.6515] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
97 Fung J, Lai CL, Yuen MF. Management of chronic hepatitis B in severe liver disease. World J Gastroenterol 2014;20:16053-61. [PMID: 25473157 DOI: 10.3748/wjg.v20.i43.16053] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
98 Kumada T, Toyoda H, Yasuda S, Miyake N, Ito T, Tanaka J. Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis. J Viral Hepat 2021;28:508-16. [PMID: 33306854 DOI: 10.1111/jvh.13457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Kim MN, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Song KJ, Park YN, Han KH. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 2015;61:1851-1859. [PMID: 25643638 DOI: 10.1002/hep.27735] [Cited by in Crossref: 94] [Cited by in F6Publishing: 76] [Article Influence: 15.7] [Reference Citation Analysis]
100 Zeng DW, Dong J, Zhang JM, Zhu YY, Jiang JJ, Liu YR. HBeAg-negative chronic hepatitis patients should be monitored more strictly: a cross-sectional retrospective study on antiviral treatment-naïve patients. J Med Virol 2015;87:1682-8. [PMID: 25965250 DOI: 10.1002/jmv.24217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
101 Liu L. Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy. Infect Agent Cancer 2020;15:8. [PMID: 32042307 DOI: 10.1186/s13027-020-0277-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
102 Liang K, Hsu C, Chang M, Chen Y, Lai M, Yeh C. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. J Infect Dis 2016;213:966-74. [DOI: 10.1093/infdis/jiv547] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
103 Matsuzaki K, Seki T, Okazaki K. TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases. J Gastroenterol 2014;49:971-81. [PMID: 24263677 DOI: 10.1007/s00535-013-0910-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
104 Liaw Y. Impact of Therapy on the Long-Term Outcome of Chronic Hepatitis B. Clinics in Liver Disease 2013;17:413-23. [DOI: 10.1016/j.cld.2013.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
105 Zhang W, Wang X, Wang Y, Zhao X, Duan W, Wang Q, Wu X, Kong Y, Ma H, You H, Ou X, Jia J. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up. Medicine (Baltimore) 2017;96:e8454. [PMID: 29095292 DOI: 10.1097/MD.0000000000008454] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
106 Rockey DC. Liver Fibrosis Reversion After Suppression of Hepatitis B Virus. Clin Liver Dis. 2016;20:667-679. [PMID: 27742006 DOI: 10.1016/j.cld.2016.06.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
107 Wong WW, Woo G, Heathcote EJ, Krahn M. Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol 2013;27:137-47. [PMID: 23516678 DOI: 10.1155/2013/924640] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
108 Jang JW, Choi JY, Kim YS, Yoo JJ, Woo HY, Choi SK, Jun CH, Lee CH, Sohn JH, Tak WY. Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2018;. [PMID: 29753085 DOI: 10.1016/j.cgh.2018.04.063] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
109 Singal AK, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther. 2013;38:98-106. [PMID: 23713520 DOI: 10.1111/apt.12344] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 12.1] [Reference Citation Analysis]
110 Chen CH, Lee CM, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Wang JH, Lee MH, Peng CY. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. Oncotarget 2017;8:92431-41. [PMID: 29190928 DOI: 10.18632/oncotarget.21369] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
111 Shen YC, Hsu C, Cheng CC, Hu FC, Cheng AL. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology. 2012;82:275-289. [PMID: 22555181 DOI: 10.1159/000337293] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
112 Su T, Kao J. Improving clinical outcomes of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;9:141-54. [DOI: 10.1586/17474124.2015.960398] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
113 Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol. 2013;19:8822-8830. [PMID: 24379605 DOI: 10.3748/wjg.v19.i47.8822] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
114 Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147:143-151.e5. [PMID: 24704525 DOI: 10.1053/j.gastro.2014.03.048] [Cited by in Crossref: 192] [Cited by in F6Publishing: 181] [Article Influence: 27.4] [Reference Citation Analysis]
115 Kim JH, Ko SY, Choe WH, Kwon SY, Lee CH. Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. Clin Mol Hepatol. 2013;19:273-279. [PMID: 24133665 DOI: 10.3350/cmh.2013.19.3.273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
116 Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64:800-806. [PMID: 26678008 DOI: 10.1016/j.jhep.2015.11.035] [Cited by in Crossref: 183] [Cited by in F6Publishing: 164] [Article Influence: 30.5] [Reference Citation Analysis]
117 Yu J, Ye Y, Liu J, Xu Y, Lou B, Zhu J, Sheng X, Feng X, Pan Q, Yang J, Cao H, Li L. The role of hepatitis B core-related antigen in predicting hepatitis B virus recurrence after liver transplantation. Aliment Pharmacol Ther 2019;50:1025-36. [PMID: 31339175 DOI: 10.1111/apt.15429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
118 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 949] [Article Influence: 179.3] [Reference Citation Analysis]
119 Huang AJ, Núñez M. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression. J Int Assoc Provid AIDS Care 2015;14:360-8. [PMID: 25999329 DOI: 10.1177/2325957415586258] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
120 Maravelia P, Frelin L, Ni Y, Caro Pérez N, Ahlén G, Jagya N, Verch G, Verhoye L, Pater L, Johansson M, Pasetto A, Meuleman P, Urban S, Sällberg M. Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections. J Infect Dis 2021;223:128-38. [PMID: 31994701 DOI: 10.1093/infdis/jiaa036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
121 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]